Company intelligence / Profile preview

Angiotech Pharmaceuticals

Vancouver, British Columbia, Canada

Ownership: Private
Employees: ~2000
Development stage: Other

Overview

Angiotech has commercialized surgical devices such as the Quill Knotless Tissue-Closure Device and drug-eluting wraps for vascular and cardiac procedures; it has sold or licensed key IP to large partners but continues to manufacture and sell branded products globally[7][9][3][5].

Therapeutic areas: NephrologyHematologyDermatologyCardiovascularOther
Modalities: DeviceSmall moleculeBiologicRecombinant protein
Industry: Surgical Medical Devices

Partnerships

Johnson & Johnson (Ethicon) – IP and manufacturing agreement for Quill technology[7]

Beyond the preview

Go deeper on Angiotech Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Angiotech Pharmaceuticals.

Explore the full profile